London: Statistics from a Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's Xeloda is far better than Xeloda alone in women with HER2 positive advanced breast cancer, where the disease had progressed despite previous therapy involving Herceptin.
Basis the findings, researchers opined that, Tykerb should be checked out for its use during the early treatment of HER2 positive breast cancer.
"Patients with advanced or metastatic HER2 positive breast cancer have limited options once their cancer has progressed on trastuzumab and standard initial chemotherapy regimens. There has been a clear need for alternative treatments to help women with metastatic breast cancer in this advanced setting. Lapatinib combined with capecitabine has demonstrated superior efficacy over capecitabine alone in this group of patients and we look forward to it being made available to women suffering from this devastating disease," said lead investigator Charles Geyer, Director of Breast Medical Oncology at Allegheny General Hospital, Pittsburgh, Pennsylvania, U.S.
Women suffering HER2 positive breast cancer carry an enhanced risk of advancement of disease and death as against women suffering tumors.